| |
| |
|
| Insider
Information: |
Leonard Frank X |
| Relationship: |
|
| City: |
Malvern |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
160,098 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,706,269 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
160,098 |
|
|
| Total
Value |
$3,706,269 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Novocure Ltd |
NVCR |
|
2024-03-04 |
160,098 |
2020-09-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
46 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NVCR |
Novocure Ltd |
Chief Development OfficerOffic |
• – – |
2020-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
59,811 |
|
% |
|
| NVCR |
Novocure Ltd |
Chief Development OfficerOffic |
• – – |
2020-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,822 |
|
% |
|
| NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
• – – |
2024-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,178 |
|
% |
|
| NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
• – – |
2024-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,268 |
|
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-07-06 |
4 |
A |
$137.12 |
$21,117 |
D/D |
154 |
90,199 |
0 |
- |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-07-05 |
4 |
A |
$59.08 |
$18,431 |
D/D |
312 |
102,607 |
0 |
- |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-08-03 |
4 |
S |
$149.43 |
$49,013 |
D/D |
(328) |
89,158 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-08-02 |
4 |
S |
$69.66 |
$28,839 |
D/D |
(414) |
102,193 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-03-02 |
4 |
S |
$152.05 |
$65,383 |
D/D |
(430) |
82,668 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-09-02 |
4 |
S |
$138.23 |
$74,645 |
D/D |
(540) |
87,153 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-03-04 |
4 |
S |
$70.41 |
$39,076 |
D/D |
(555) |
103,039 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-03-04 |
4 |
S |
$137.55 |
$77,993 |
D/D |
(567) |
90,810 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-09-02 |
4 |
AS |
$79.04 |
$46,158 |
D/D |
(584) |
87,397 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-08-02 |
4 |
S |
$149.38 |
$106,507 |
D/D |
(713) |
89,486 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-03-08 |
4 |
S |
$70.10 |
$52,154 |
D/D |
(744) |
102,295 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-03-08 |
4 |
S |
$130.81 |
$100,067 |
D/D |
(765) |
90,045 |
0 |
% |
|
| NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
• – – |
2024-03-04 |
4 |
S |
$16.01 |
$13,448 |
D/D |
(840) |
160,098 |
0 |
% |
|
| NVCR |
Novocure Ltd |
President, CNS Cancers US |
• – – |
2023-03-02 |
4 |
AS |
$75.28 |
$63,535 |
D/D |
(844) |
58,144 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-03-03 |
4 |
S |
$74.50 |
$69,283 |
D/D |
(930) |
103,594 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-09-06 |
4 |
AS |
$78.57 |
$108,741 |
D/D |
(1,384) |
86,013 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2021-02-27 |
4 |
OE |
$149.10 |
$218,432 |
D/D |
1,465 |
83,098 |
0 |
- |
|
| NVCR |
Novocure Ltd |
EVP, Pres., Novocure Oncology |
• – – |
2024-03-01 |
4 |
S |
$16.03 |
$26,909 |
D/D |
(1,679) |
160,938 |
0 |
% |
|
| NVCR |
Novocure Ltd |
President, CNS Cancers US |
• – – |
2023-03-01 |
4 |
S |
$76.36 |
$128,594 |
D/D |
(1,684) |
63,095 |
0 |
% |
|
| NVCR |
Novocure Ltd |
Chief Development Officer |
• – – |
2022-09-09 |
4 |
AS |
$88.00 |
$163,944 |
D/D |
(1,863) |
84,150 |
0 |
% |
|
| NVCR |
Novocure Ltd |
President, CNS Cancers US |
• – – |
2023-03-03 |
4 |
AS |
$77.64 |
$159,859 |
D/D |
(2,059) |
67,893 |
0 |
% |
|
46 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
